Allogeneic core amino acids of an immunodominant allopeptide are important for MHC binding and TCR recognition

Human Immunology
Ana Gabriela SitaruChristoph Otto

Abstract

The indirect alloimmune response seems to be restricted to a few dominant major histocompatibility complex (MHC)-derived peptides responsible for T-cell activation in allograft rejection. The molecular mechanisms of indirect T-cell activation have been studied using peptide analogues derived from the dominant allopeptide in vitro, whereas the in vivo effects of peptide analogues have not been well characterized yet. In the present study, we generated allochimeric peptide analogues by replacing the three allogeneic amino acids 5L, 9L, and 10T in the sequence of the dominant MHC class I allopeptide P1. These allochimeric peptide analogues were used to define the allogeneic amino acids critical for the MHC binding and TCR recognition. We found that position 5 (5L) of the dominant allopeptide acts as an MHC-binding residue, while the other two allogeneic positions, 9 and 10, are important for the T-cell receptor (TCR) recognition. A peptide containing the MHC-binding residue 5L, as the only different amino acid between donor (RT1.A(u)) and recipient (RT1.A(l)) sequences, did not induce proliferation of lymph node cells primed with the dominant peptide and prevented dominant peptide-induced acceleration of allograft rejection. Ident...Continue Reading

References

Feb 1, 1969·The Journal of Thoracic and Cardiovascular Surgery·K Ono, E S Lindsey
Jan 1, 1995·Immunogenetics·H G RammenseeS Stevanoviíc
May 15, 1994·Transplantation·M H SayeghC B Carpenter
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·H AuchinclossL H Glimcher
Apr 30, 1996·Proceedings of the National Academy of Sciences of the United States of America·E ZismanE Mozes
Jan 1, 1996·International Reviews of Immunology·A I ColovaiN Suciu-Foca
Sep 1, 1996·The Journal of Clinical Investigation·Z LiuN Suciu-Foca
Nov 1, 1996·The Journal of Experimental Medicine·N R KriegerC G Fathman
Apr 1, 1997·Proceedings of the National Academy of Sciences of the United States of America·Y Katz-LevyE Mozes
Apr 29, 1998·The Journal of Clinical Investigation·A ValujskikhP S Heeger
Oct 3, 1998·Human Immunology·G BenichouE V Fedoseyeva
Feb 19, 2000·Current Opinion in Immunology·S I Abrams, J Schlom
Nov 9, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·M García-PeydróJ A Castro
Aug 18, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·P J RuizL Steinman
Oct 25, 2001·Journal of the American Society of Nephrology : JASN·Karl L WomerMohamed H Sayegh
Nov 3, 2001·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·B Bielekova, R Martin
May 23, 2002·Transplantation·Alain Le MoineDaniel Abramowicz
Jul 10, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·S I ReznikT Mohanakumar
Aug 8, 2002·Clinical Immunology : the Official Journal of the Clinical Immunology Society·H J KimA Bar-Or
Oct 9, 2002·Human Immunology·Ana Gabriela SitaruChristoph Otto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.